89004-82-0

Usage

Uses

Used in Organic Synthesis:
Potassium Bis(Boc)amide is used as a reagent for the synthesis of a wide range of compounds. Its role in providing the Boc protecting group is essential in blocking the reactivity of functional groups, allowing for selective reactions to occur.
Used as a Base in Organic Reactions:
In various organic reactions, Potassium Bis(Boc)amide is utilized as a base. Its basic properties enable it to participate in deprotonation and other processes that facilitate the formation of desired products.
Used as a Catalyst in Chemical Processes:
Potassium Bis(Boc)amide also serves as a catalyst in certain chemical processes. Its catalytic activity helps to increase the rate of reactions, making the synthesis of specific compounds more efficient.
Used in the Advancement of Chemical Research and Development:
Due to its multifaceted role in organic synthesis, as a base, and as a catalyst, Potassium Bis(Boc)amide is instrumental in the advancement of chemical research and development. Its ability to facilitate the synthesis of a broad spectrum of compounds makes it an indispensable tool in the field of organic chemistry.

Upstream product

• 1310-58-3 potassium hydroxide 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 

Downstream Products

• 115269-99-3 N,N-bis(tert-butoxycarbonyl)allylamine 
• 566905-93-9 benzyl 4-{3-[bis(tert-butoxycarbonyl)amino]propyl}piperidine-N-carboxylate 
• 566905-91-7 benzyl 4-{[bis(tert-butoxycarbonyl)amino]methyl}piperidine-N-carboxylate 
• 566905-92-8 benzyl 4-{2-[bis(tert-butoxycarbonyl)amino]ethyl}piperidine-N-carboxylate 
• 566905-94-0 benzyl 4-{4-[bis(tert-butoxycarbonyl)amino]butyl}piperidine-N-carboxylate 
• 1073159-93-9 di-BOC-5-methyl-2-nitrobenzylamine 
• 1073159-88-2 3-methyl-2-nitro-benzyl di-tert-butyl iminodicarboxylate 
• 566906-02-3 2-(4-{4-[bis(tert-butoxycarbonyl)amino]butyl}piperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate 
• 566906-01-2 2-(4-{3-[bis(tert-butoxycarbonyl)amino]propyl}piperidin-1-yl)ethyl 4 amino-5-chloro-2-methoxybenzoate 
• 566906-00-1 2-(4-{2-[bis(tert-butoxycarbonyl)amino]ethyl}piperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate 
• 566905-99-5 2-(4-{[bis(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate 
• 705951-13-9 C₂₇H₄₀N₂O₇ 
• 705951-12-8 C₂₆H₃₈N₂O₇ 

Relevant academic research and scientific papers

BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters

Background and Purpose: 4-Methyl-N-methylcathinone (mephedrone) is a synthetic stimulant that acts as a substrate-type releaser at transporters for dopamine (DAT), noradrenaline (NET) and 5-HT (SERT). Upon systemic administration, mephedrone is metabolized to several phase I compounds: the N-demethylated metabolite, 4-methylcathinone (nor-mephedrone); the ring-hydroxylated metabolite, 4-hydroxytolylmephedrone (4-OH-mephedrone); and the reduced keto-metabolite, dihydromephedrone. Experimental Approach: We used in vitro assays to compare the effects of mephedrone and synthetically prepared metabolites on transporter-mediated uptake and release in HEK293 cells expressing human monoamine transporters and in rat brain synaptosomes. In vivo microdialysis was employed to examine the effects of i.v. metabolite injection (1 and 3?mg·kg?1) on extracellular dopamine and 5-HT levels in rat nucleus accumbens. Key Results: In cells expressing transporters, mephedrone and its metabolites inhibited uptake, although dihydromephedrone was weak overall. In cells and synaptosomes, nor-mephedrone and 4-OH-mephedrone served as transportable substrates, inducing release via monoamine transporters. When administered to rats, mephedrone and nor-mephedrone produced elevations in extracellular dopamine and 5-HT, whereas 4-OH-mephedrone did not. Mephedrone and nor-mephedrone, but not 4-OH-mephedrone, induced locomotor activity. Conclusions and Implications: Our results demonstrate that phase I metabolites of mephedrone are transporter substrates (i.e. releasers) at DAT, NET and SERT, but dihydromephedrone is weak in this regard. When administered in vivo, nor-mephedrone increases extracellular dopamine and 5-HT in the brain whereas 4-OH-mephedrone does not, suggesting the latter metabolite does not penetrate the blood–brain barrier. Future studies should examine the pharmacokinetics of nor-mephedrone to determine its possible contribution to the in vivo effects produced by mephedrone.

SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Multicyclic bis-amide MMP inhibitors

The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

Direct Synthesis of N-Protected Chiral Amino Acids from Imidodicarbonates employing either Mitsunobu or Triflate Alkylation. Feasibility Study using Lactate with Particular Reference to 15N-Labelling

Two novel approaches to N,N-diprotected chiral α-amino acid esters, based on selected imidodicarbonates as amine synthons, have been explored.Thus, N-alkylation of these substrates was smoothly accomplished by the Gabriel or Mitsunobu methods as well as by the use of triflates.Ethyl (R,S)-2-bromopropionate underwent nucleophilic substitution when treated with the potassium salt of selected imidodicarbonates in dry dimethylformamide to furnish the corresponding fully blocked (R,S)-alanines in high yield. the chirality of ethyl (S)-lactate was largely conserved when it was condensed with free imidodicarbonates and tosylcarbamates under conventional Mitsunobu conditions.The yield of the corresponding N,N-di-protected ethyl (R)-alaninate was strongly dependent of the electron-withdrawing properties of the imidodicarbonate alkyl groups.Thus, Boc2NH gave 5 percent of the product whereas Troc-NH-Z afforded the corresponding analogue in 83 percent yield under comparable conditions.On the other hand, triflates of various lactic acid esters reacted smoothly with the lithium salt of Boc2NH, also with clean inversion, as a result of which, after selective removal of two blocking groups, the N-protected alanine of opposite configuration could be isolated in high yield and excellent stereochemical purity.Both methods have been used for the synthesis of 15N-labelled N-protected (R)- and (S)-alanines, suitable for direct application to peptide synthesis.